OncoTherapy Science, Inc. (JP:4564)

:4564

4564

OncoTherapy Science

RESEARCH TOOLSreports

Want to see JP:4564 full AI Analyst Report?

OncoTherapy Science (4564) Price & Analysis

2 Followers

4564 Stock Chart & Stats

¥21.00

-¥1.00(-4.17%)

At close: Jan 08 4:00 PM EST

¥21.00

-¥1.00(-4.17%)

Day’s Range― - ―

52-Week Range¥19.00 - ¥35.00

Previous CloseN/A

Volume4.29M

Average Volume (3M)39.41M

Market Cap

¥7.57B

Enterprise Value¥5.97B

Total Cash (Recent Filing)¥1.23B

Total Debt (Recent Filing)¥37.14M

Price to Earnings (P/E)―

Beta0.45

Next Earnings

Jan 29, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.03

Shares Outstanding398,643,700

10 Day Avg. Volume60,218,049

30 Day Avg. Volume39,409,347

Financial Highlights & Ratios

PEG Ratio0.67

Price to Book (P/B)3.22

Price to Sales (P/S)8.53

P/FCF Ratio-7.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Zero DebtZero reported debt provides durable financial flexibility for a cash-burning biotech: it reduces default risk, lowers interest obligations, and preserves borrowing capacity for R&D or strategic transactions. Over 2–6 months this supports survivability while clinical programs progress.

Improved Equity Capital CushionA material increase in equity strengthens the capital base and extends runway potential without adding leverage. This durable improvement makes near-term external financings less urgent or dilutive and enhances the company's ability to fund trials or partnerships over several months.

Oncology-focused R&D PlatformA focused oncology and tumor-specific immune approach targets high unmet medical need and aligns with sustained demand for cancer therapeutics. This structural positioning supports long-term partnership, licensing, and clinical development opportunities that remain relevant beyond short-term market moves.

Bears Say

Persistent Cash BurnConsistently deep negative operating and free cash flow means the business depends on external funding to continue operations. Over 2–6 months this raises dilution and execution risk if financing windows close, and it constrains the company’s ability to scale or fund costly late-stage studies independently.

Revenue Volatility And Recent DeclineVolatile revenue with a recent decline signals unstable commercial traction or milestone timing, complicating planning for development spend and partner negotiations. In a 2–6 month horizon, this undermines predictable cash inflows and makes funding needs and valuation of programs more uncertain.

Large Operating Losses; Weak MarginsOperating losses roughly matching revenue indicate that the business is not yet generating scalable economics. Sustained negative margins limit the ability to self-fund R&D or commercialization and increase reliance on partners or capital markets, creating durable execution and dilution risk.

4564 FAQ

What was OncoTherapy Science, Inc.’s price range in the past 12 months?

OncoTherapy Science, Inc. lowest stock price was ¥19.00 and its highest was ¥35.00 in the past 12 months.

What is OncoTherapy Science, Inc.’s market cap?

OncoTherapy Science, Inc.’s market cap is ¥7.57B.

When is OncoTherapy Science, Inc.’s upcoming earnings report date?

OncoTherapy Science, Inc.’s upcoming earnings report date is Jan 29, 2027 which is in 232 days.

How were OncoTherapy Science, Inc.’s earnings last quarter?

OncoTherapy Science, Inc. released its earnings results on Feb 06, 2026. The company reported -¥0.63 earnings per share for the quarter, missing the consensus estimate of N/A by -¥0.63.

Is OncoTherapy Science, Inc. overvalued?

According to Wall Street analysts OncoTherapy Science, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does OncoTherapy Science, Inc. pay dividends?

OncoTherapy Science, Inc. does not currently pay dividends.

What is OncoTherapy Science, Inc.’s EPS estimate?

OncoTherapy Science, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does OncoTherapy Science, Inc. have?

OncoTherapy Science, Inc. has 398,643,700 shares outstanding.

What happened to OncoTherapy Science, Inc.’s price movement after its last earnings report?

OncoTherapy Science, Inc. reported an EPS of -¥0.63 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of OncoTherapy Science, Inc.?

Currently, no hedge funds are holding shares in JP:4564

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

OncoTherapy Science, Inc.

OncoTherapy Science, Inc. is a Japanese biotechnology firm dedicated to the discovery and advancement of innovative cancer treatments. Established in 2001 and headquartered in Kawasaki, Japan, the company's robust pipeline spans various therapeutic modalities. Among its small-molecule compounds, OTS167, an inhibitor of maternal embryonic leucine zipper kinase, is undergoing Phase I/II clinical trials for acute myeloid leukemia and Phase I trials for breast cancer. Another small-molecule asset, OTS964, targets T-LAK cell-originated protein kinase for a range of oncological conditions. The company's oncology peptide vaccine candidates include S-588410, which is in Phase III trials for esophageal cancer and Phase II for bladder cancer. S-488210 is progressing through Phase I/II clinical trials for head and neck cancer, while S-588210 is in Phase I for solid malignancies. In its antibody drug portfolio, OTSA101 is in Phase I clinical trials for synovial sarcoma. Notably, KHK6640, an anti-amyloid beta peptide antibody, is also in Phase I trials, targeting Alzheimer's disease – indicating a broader therapeutic scope. Beyond drug development, OncoTherapy Science, Inc. also provides specialized contract analysis services.